Hypocalcemia Clinical Trial
Official title:
A Phase II Study of Short-Term Use of Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia
Primary Objective:
-To identify the optimal dose of a seven-day course of twice-daily teriparatide as compared
to standard therapy for hypocalcemia in patients after total thyroidectomy and/or extensive
neck dissections (pharyngectomy, laryngectomy,unilateral, bilateral / central neck,
mediastinal lymph node neck dissections), with which serum calcium will be raised to
corrected serum calcium levels of 8-10.5mg/dL and maintained within this range until the end
of the treatment course.
Teriparatide is designed to act like a natural human hormone called parathyroid hormone,
which can increase the blood levels of calcium. Calcium plus calcitriol is considered the
standard treatment for low calcium in the blood.
After scheduled surgery, the level of calcium in the blood will be monitored according to
the standard of care. Between 18 and 24 hours after the surgery, if calcium level drops
below an acceptable level, or participants develop symptoms of low calcium, they will be
randomly assigned (as in the toss of a coin) to 1 of 4 groups. One group (the
"standard-of-care" group) will receive calcium plus calcitriol alone, for 7 days. The other
groups (the "teriparatide" groups) will receive 1 of 3 different dose levels of teriparatide
for 7 days, plus calcium and calcitriol for 7 days. There is an equal chance of getting
assigned to any of these 4 groups, for the first 40 participants enrolled on this study. If
enrolled after that point, participants will have a greater chance of being assigned to the
group showing the best results.
Standard-of-Care Group:
If assigned to the standard-of-care group, participant will receive calcium and calcitriol
according to the standard schedule and dose. The calcium will either be given through a vein
or by mouth, and calcitriol will be given by mouth.
Teriparatide Group:
If assigned to a teriparatide group, participant will receive teriparatide by an injection
under the skin, twice a day for 7 days. They will be taught how to perform the injections
themselves, with a pen-sized device. While in the hospital, the hospital staff will watch
them perform the injections and offer help, if needed. If discharged from the hospital and
sent home before the 7 days of therapy are complete, they will continue giving themselves
the injections (through Day 7) at home. The pen should not be removed from refrigeration for
more than 2 -4 hours. Depending on what dose level of teriparatide assigned to receive, they
may have to give themselves up to 3 injections each time. In addition to teriparatide, they
will receive calcium and calcitriol, according to the standard schedule and dose. The
calcium will either be given through a vein or by mouth, and calcitriol by mouth.
Both Groups:
If blood calcium level has not returned to normal after the 7 days of treatment,
participants may need to continue receiving calcium and/or calcitriol for as long as the
doctor decides it is necessary.
They will be asked to keep a medication log (diary) of when they take the teriparatide
and/or calcium/calcitriol. The log should be returned to the research nurse on Day 8.
On Days 1-7, blood will be drawn to check the level of calcium twice a day (while in the
hospital) or once a day (while treated as an outpatient). These blood draws (about 1
teaspoon each time) will be performed 2 hours before receiving teriparatide and/or
calcium/calcitriol.
Blood will also be drawn to check calcium and parathyroid hormone levels after the study
treatment is over. The first of these blood draws (about 1 tablespoon each time) will be
performed at 3 days after receiving last dose of teriparatide and/or last dose of
calcium/calcitriol. The second blood draw will be performed at 4 weeks after the surgery.
Starting on Day 7, and again at 4 weeks after surgery, they will be asked to collect urine
over the course of a 24-hour period so calcium levels can be measured.
From Day 1 to Day 7, if discharged from the hospital and sent home, the study personnel will
call on the phone once a day to see how participants are doing. At 3 days after receiving
the last dose of teriparatide and/or the last dose of calcium/calcitriol, and at 4 weeks
after the surgery, they will be called again.
After the urine collection, blood draw, and phone call at 4 weeks after the surgery,
participation in the study is over.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02892253 -
Parathyroid Autofluorescence Visualization in Thyroid Surgery: Impact on Postoperative Hypocalcemia
|
N/A | |
Completed |
NCT05043584 -
Near-infrared Autofluorescence (NIRAF)-Guided Total Thyroidectomy: Impact in Low-volume, Non-parathyroid Institutions
|
N/A | |
Recruiting |
NCT05885256 -
Clinical Assessment of Low Calcium In traUMa (CALCIUM)
|
||
Recruiting |
NCT04160637 -
Is There Benefit From Early Postoperative PTH Monitoring?
|
||
Completed |
NCT00506103 -
The No-Tie Technique Using the Harmonic Scalpel in Total Thyroidectomy With Central Neck Dissection: A Prospective Randomized Study
|
N/A | |
Recruiting |
NCT05585593 -
Registry for Hypoparathyroidism Wuerzburg
|
||
Recruiting |
NCT04012476 -
Determination of Parathyroid Function by Fluorescence With Indocyanine Green (ICG) After Total Thyroidectomy
|
Phase 4 | |
Recruiting |
NCT05586529 -
Effect of Preoperative High-dose Cholecalciferol in Prevention of Post-thyroidectomy Hypocalcaemia
|
N/A | |
Completed |
NCT01868750 -
Phase II Pre-operative Vitamin D Supplementation to Prevent Post-thyroidectomy Hypocalcemia
|
Phase 2 | |
Completed |
NCT00668200 -
Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®
|
Phase 4 | |
Completed |
NCT00630214 -
Prevention of Hypocalcemia in Patients Undergoing Total Thyroidectomy Plus Central Neck Dissection
|
Phase 2 | |
Not yet recruiting |
NCT03685877 -
Hypocalcemia in Infants and Children
|
||
Terminated |
NCT00001151 -
Studies With 1,25-Dihydroxycholecalciferol
|
Phase 2 | |
Completed |
NCT04750460 -
Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).
|
Phase 3 | |
Not yet recruiting |
NCT03063060 -
The Impact of Vitamin D Deficiency on Hypocalcaemia Following Total Thyroidectomy
|
N/A | |
Not yet recruiting |
NCT04304573 -
Is Correcting Total Serum Calcium Levels Important After Thyroidectomy
|
||
Recruiting |
NCT05216419 -
Prevention of Postoperative Hypocalcemia of Oral Vitamin D Supplementation Before Total Thyroidectomy
|
Phase 4 | |
Recruiting |
NCT04775381 -
Total Post-thyroidectomy Hypocalcemia After Preoperative Cholecalciferol Supplementation
|
Phase 3 | |
Active, not recruiting |
NCT01632514 -
Vitamin D Deficiency and Postoperative Hypocalcemia
|
Phase 4 | |
Recruiting |
NCT05260255 -
Effect of Vitamin D Supplement on Disease Activity in SLE
|
N/A |